AiiM OLE
14 evidence topics · 3 sources
Objective
Registered purpose of the extension study
Company statement of the extension study objective
Extension data intended for the label
Location and study date
Registry dates for the extension study
| Milestone | Registry record |
|---|---|
| First posted | “2026-09-08” |
| Study start (estimated) | “2026-09-30” |
| Primary completion (estimated) | “2029-07-31” |
| Study completion (estimated) | “2029-07-31” |
Registered extension study sites
“Retina Group of Florida” (opens the source at this quote in a new tab)
“Retina Vitreous Associates of Florida” (opens the source at this quote in a new tab)
“Cumberland Valley Retina Consultants” (opens the source at this quote in a new tab)
“Mid Atlantic Retina Specialists” (opens the source at this quote in a new tab)
“Asheville Eye Associates - Retina Division” (opens the source at this quote in a new tab)
“Verum Research, LLC” (opens the source at this quote in a new tab)
Extension study identifiers
| Item | Registry record |
|---|---|
| Sponsor protocol number | “ANX007-GA-03” |
| EU CT number | “2026-527023-96-00” |
| Acronym | “AiiM OLE” |
Study design
Entry into the extension after the ARCHER II Month 24 visit
Regulatory acceptance of the extension study data
Eligibility criteria
Registered inclusion and exclusion criteria for the extension study
Treatment
Registered extension study arm and intervention
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome of the extension study
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the extension study
| Item | Registry record |
|---|---|
| Estimated enrollment | “605” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: extension study not yet started
The AiiM OLE study (NCT07807969) was registered as not yet recruiting, with an estimated start date of September 30, 2026 and an estimated primary completion date of July 31, 2029, so no participant data exist. It is a single-group, open-label design with no masking and no comparator arm, and its registered primary outcome is the number of participants with treatment-emergent adverse events through Month 24; any efficacy observations it yields will lack a concurrent control. Enrollment is limited to participants who completed ARCHER II and had not permanently ceased their assigned masked treatment at or before the Month 24 visit, so the extension population is a selected subset of the ARCHER II population. The company states that the extension is designed to evaluate the “longer-term profile of vonaprument for inclusion in the label”, and its 10-Q states that there is no assurance that regulators will accept data from the OLE study.